MREO vs. VERA, IOVA, PRAX, GLPG, WVE, APGE, EVO, IRON, ARQT, and AMPH
Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Vera Therapeutics (VERA), Iovance Biotherapeutics (IOVA), Praxis Precision Medicines (PRAX), Galapagos (GLPG), Wave Life Sciences (WVE), Apogee Therapeutics (APGE), Evotec (EVO), Disc Medicine (IRON), Arcutis Biotherapeutics (ARQT), and Amphastar Pharmaceuticals (AMPH). These companies are all part of the "pharmaceutical products" industry.
Mereo BioPharma Group vs.
Mereo BioPharma Group (NASDAQ:MREO) and Vera Therapeutics (NASDAQ:VERA) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends.
Mereo BioPharma Group's return on equity of 0.00% beat Vera Therapeutics' return on equity.
Mereo BioPharma Group received 10 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 79.03% of users gave Mereo BioPharma Group an outperform vote while only 65.00% of users gave Vera Therapeutics an outperform vote.
Mereo BioPharma Group has a beta of 0.91, indicating that its share price is 9% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 4.1% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 21.7% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Mereo BioPharma Group has higher revenue and earnings than Vera Therapeutics.
Mereo BioPharma Group currently has a consensus price target of $7.83, suggesting a potential upside of 174.37%. Vera Therapeutics has a consensus price target of $65.44, suggesting a potential upside of 128.99%. Given Mereo BioPharma Group's stronger consensus rating and higher probable upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Vera Therapeutics.
In the previous week, Vera Therapeutics had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 6 mentions for Vera Therapeutics and 2 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.86 beat Vera Therapeutics' score of 0.16 indicating that Mereo BioPharma Group is being referred to more favorably in the media.
Summary
Mereo BioPharma Group beats Vera Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Mereo BioPharma Group News Delivered to You Automatically
Sign up to receive the latest news and ratings for MREO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mereo BioPharma Group Competitors List
Related Companies and Tools
This page (NASDAQ:MREO) was last updated on 2/21/2025 by MarketBeat.com Staff
Free MREO Stock Alerts